David Meininger

David Meininger

Company: Link Immunotherapeutics Inc.

Job title: Co-founder & Chief Executive Officer


Panel Discussion: The Relevance & Importance of CRS in Solid Tumors 12:00 pm

Questioning which learnings from the advancements and approvals in liquid tumors are transferable to solid tumors Evaluating if there is a risk of CRS in a solid tumor indication, what can be done to predict and mitigate it Discuss whether CRS will present in a similar way for solid tumor patients compared to liquid tumorsRead more

day: Day Two

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.